Scintigraphic assessment of drug delivery from the ultrahaler dry powder inhaler

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 10, Issue 4, 1997, Pages 295-306

  Pitcairn, G R ^a   Lim, J ^b   Hollingworth, A ^b   Newman, S P ^a  

^a PHARMACEUTICAL PROFILES LTD   (United Kingdom)

^b SANOFI   (France)

Author keywords

Dry powder inhaler; Metered dose inhaler; Nedocromil sodium

Indexed keywords

NEDOCROMIL SODIUM; PERTECHNETIC ACID TC 99M;

ARTICLE; ASTHMA; CHRONIC LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRY POWDER; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; LUNG SCINTISCANNING; MALE; METERED DOSE INHALER; NORMAL HUMAN;

EID: 0031455263     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/jam.1997.10.295     Document Type: Article

References (32)

1. Crompton, G.K. 1982. Problems patients have using pressurised aerosol inhalers. Eur. J. Respir. Dis. 63 (Supplement 119):101-104.
2. Newman, S.P. Metered dose pressurised aerosols and the ozone layer. 1990. Eur. Respir. J. 3:495-497.
3. Ganderton, D., and N.M. Kassem. 1992. Dry powder inhalers. In D. Ganderton, T. Jones, eds. Advances in Pharmaceutical Sciences, vol. 6. Academic Press, London, 165-191.
4. Crompton, G.K. 1991. Dry powder inhalers: Advantages and limitations. J. Aerosol Med. 4:151-155.
5. Corbett, J.S., J.L. Hart, R. Jansen, M.T. Shepard, and P. Wright. 1993. Rotary planar multi-dose powder inhaler. J. Aerosol Med. 6(Suppl):72.
6. Newman, S.P. 1993. Scintigraphic assessment of therapeutic aerosols. Crit. Rev. Therap. Drug Car. Sys. 10:65-109.
7. Auty, R.M., K. Brown, M.G. Neale, and P.D. Snashall. 1987. Respiratory tract deposition of sodium cromoglycate is highly dependent upon technique of inhalation using the spinhaler. Br. J. Dis. Chest 81:371-380.
8. Richards, R., S.F. Simpson, A.G. Renwick, and S.T. Holgate. 1988. Inhalation rate of sodium cromoglycate determines plasma pharmacokinetics and protection against AMP-induced bronchoconstriction in asthma. Eur. Respir. J. 1:896-901.
9. Pitcairn, G.R., G. Lunghetti, P. Ventura, and S.P. Newman. 1994. A comparison of the lung deposition of salbutamol inhaled from a new dry powder inhaler, at two inhaled flow rates. Int. J. Pharm. 102:11-18.
10. Newman, S.P., A.R. Clark, N. Talaee, and S.W. Clarke. 1989. Pressurised aerosol deposition in the human lung with and without an "open" spacer device. Thorax 44:706-710.
11. Newman, S.P., A.W.B. Weisz, N. Talaee, and S.W. Clarke. 1991. Improvement of drug delivery with a breath-actuated pressurised aerosol for patients with poor inhaler technique. Thorax 46:712-716.
12. Quanjer, P.H. 1983. Standardised lung function testing. Bull. Eur. Physiopathol. Respir. 19(Supplement 5):7-95.
13. Pitcairn, G.R., and S.P. Newman. 1996. Tissue attenuation corrections in gamma scintigraphy. J. Aerosol Med. 10:187-198.
14. Summers, Q.A., A.R. Clark, A. Hollingworth, J. Fleming, and S.T. Holgate. 1990. The preparation of a radiolabelled aerosol of nedocromil sodium for administration by metered dose inhaler that accurately preserves particle size distribution of the drug. Drug Invest. 2:90-98.
15. Jaegfeldt, H., J.A.R. Andersson, E. Trofast, and K.I.L. Wetterlin. 1987. Particle size distribution from different modifications of Turbuhaler. In S.P. Newman, F. Morén, G.K. Crompton, eds. A new concept in inhalation therapy. Medicom, Bussum, 90-98.
16. Zanen, P., P.I. Van Spiegel, H. Van der Kolk, E. Tushuizen, and R. Enthoven. 1992. The effect of the inhalation flow on the performance of a dry powder inhalation system. Int. J. Pharm. 81:199-203.
17. ®. STP Pharma Sciences 4(1):33-37.
18. Thorsson, L., S. Edsbäcker, and T-B. Conradson. 1994. Lung deposition of budesonide from Turbuhaler is twice that from a pressurised metered dose inhaler P-MDI. Eur. Respir. J. 7:1839-1844.
19. Olsson, B., L. Borgström, L. Asking, and E. Bondesson. 1996. Effect of inlet throat on the correlation between measured fine particle dose and lung deposition. In R.N. Dalby, P.R. Bryon, and S.J. Farr, eds. Respiratory drug delivery V. Interpharm Press, Buffalo, 273-281.
20. Newman S.P., F. Morén, E. Trofast, N. Talaee, and S.W. Clarke. 1991. Terbutaline sulphate Turbuhaler: Effect of inhaled flow rate on drug deposition and efficacy. Int. J. Pharm. 74:209-213.
21. Borgström, L., E. Bondesson, F. Morén, E. Trofast, and S.P. Newman. 1994. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur. Respir. J. 7:69-73.
22. Biddiscombe, M.F., R. Melchor, V.H.F. Mak, R.J. Marriott, A.J. Taylor, M.D. Short, and S.G. Spiro. 1993. The lung deposition of salbutamol, directly labelled with Tc-99m, delivered by pressurised metered dose inhalers and dry powder inhalers. Int. J. Pharm. 91:111-121.
23. Borgström, L., and S.P. Newman. 1993. Total and regional lung deposition of terbutaline sulphate inhaled via a pressurised MDI or via Turbuhaler. Int. J. Pharm. 97:47-53.
24. Newman, S.P., A. Hollingworth, and A.R. Clark. 1994. Effect of different modes of inhalation on drug delivery from a dry powder inhaler. Int. J. Pharm. 102:127-132.
25. Biddiscombe, M.F., R. Melchor, V.H.F. Mak, R.J. Marriott, A.J. Taylor, M.D. Short, and S.G. Spiro. 1993. The lung deposition of salbutamol, directly labelled with Tc-99m, delivered by pressurised metered dose inhalers and dry powder inhalers. Int. J. Pharm. 91:111-121.
26. Pitcairn, G.R., T. Lankinen, E. Valkila, and S.P. Newman. 1995. Lung deposition of salbutamol from the Leiras metered dose powder inhaler. J. Aerosol Med. 8:307-311.
27. Pitcairn, G.R., G. Hooper, X. Luria, X. Rivero, and S.P. Newman. 1996. A scintigraphic study to evaluate the deposition patterns of a novel anti-asthma drug inhaled from the Cyclohaler dry powder inhaler. Adv. Drug Del. Rev. 26:59-67.
28. Vidgren, M., J. Arppe, P. Vidgren, M., Silvasti, and H. Tukiainen. 1994. Pulmonary deposition of Tc-99m labelled salbutamol particles in healthy volunteers after inhalation from a metered dose inhaler and from a novel multiple dose powder inhaler. STP Pharma Sciences 4:29-32.
29. Zainudin, B.M.Z., M. Biddiscombe, S.E.J. Tolfree, M. Short, S.G. Spiro. 1990. Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a metered dose inhaler, as a dry powder, and as a nebulised solution. Thorax 45:469-473.
30. Newman S.P., A.R. Clark, N. Talaee, and S.W. Clarke. 1991. Lung deposition of 5 mg Intal from a pressurised metered dose inhaler assessed by radiotracer technique. Int. J. Pharm. 74:203-208.
31. Borgström, L., and M. Nilsson. 1990. A method for determination of the absolute pulmonary bioavailability of inhaled drugs: Terbutaline. Pharm. Res. 1068-1070.
32. Melchor, R., M.F. Biddiscombe, V.H.F. Mak, M.D. Short, and S.G. Spiro. 1993. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax 48:506-511.